Skip to main content
Figure 1 | Journal of Translational Medicine

Figure 1

From: The natural history of EGFR and EGFRvIII in glioblastoma patients

Figure 1

Graph showing Kaplan-Meier estimates of overall survival in glioblastoma multiforme patients who underwent sub-total resection followed by standard-of-care radiation therapy and chemotherapy. Patients with tumors not expressing the epidermal growth factor receptor (EGFR; n = 23; solid black line), expressing amplified EGFR (n = 14; dashed grey line), and expressing EGFRvIII (n = 17; dotted black line) had median overall survival times of 12.3 (95% CI, 8.04–16.56), 11.03 (95% CI, 10.18–11.89), and 14.07 (95% CI, 7.39–20.74) months, respectively, which were not statistically significantly different.

Back to article page